Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of sintilimab combined with regorafenib and HAIC in
patients with colorectal liver metastasis who failed second-line therapy
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital